News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
70,011 Results
Type
Article (1922)
Company Profile (2)
Press Release (68087)
Section
Business (21469)
Career Advice (9)
Deals (4553)
Drug Development (8162)
FDA (1804)
Job Trends (800)
News (37032)
Policy (3564)
Tag
Academia (94)
Allergies (7)
Alliances (8137)
ALS (6)
Alzheimer's disease (123)
Antibody-drug conjugate (ADC) (16)
Approvals (1837)
Artificial intelligence (14)
Automation (1)
Bankruptcy (8)
Best Places to Work (585)
Biosimilars (22)
Biotechnology (5)
Bladder cancer (11)
Brain cancer (2)
Breast cancer (21)
Cancer (221)
Cardiovascular disease (5)
Career advice (9)
CAR-T (4)
Cell therapy (25)
Clinical research (7036)
Collaboration (95)
Compensation (9)
Complete response letters (2)
COVID-19 (185)
C-suite (16)
Cystic fibrosis (4)
Data (202)
Depression (1)
Diabetes (14)
Diagnostics (598)
Digital health (1)
Drug discovery (13)
Duchenne muscular dystrophy (12)
Earnings (7644)
Events (7006)
Executive appointments (49)
FDA (1956)
Fibrodysplasia Ossificans Progressiva (1)
Funding (62)
Gene editing (3)
Gene therapy (19)
GLP-1 (45)
Government (234)
Grass and pollen (1)
Guidances (4)
Healthcare (1077)
IgA nephropathy (4)
Immunology and inflammation (2)
Indications (3)
Infectious disease (192)
Inflammatory bowel disease (17)
Influenza (6)
Intellectual property (17)
IPO (1625)
Job creations (241)
Job search strategy (9)
Layoffs (6)
Legal (951)
Liver cancer (16)
Lung cancer (36)
Lymphoma (14)
Manufacturing (31)
MASH (7)
Medical device (1122)
Medtech (1123)
Mergers & acquisitions (3024)
Metabolic disorders (39)
Multiple sclerosis (8)
NASH (1)
Neurodegenerative disease (7)
Neuroscience (168)
NextGen: Class of 2025 (219)
Non-profit (61)
Northern California (138)
Obesity (16)
Opinion (1)
Ovarian cancer (10)
Pain (4)
Pancreatic cancer (8)
Parkinson's disease (15)
Partnered (2)
Patents (19)
Patient recruitment (8)
People (4964)
Pharmaceutical (3)
Phase I (1909)
Phase II (2947)
Phase III (2665)
Pipeline (126)
Postmarket research (241)
Preclinical (670)
Press Release (2)
Prostate cancer (8)
Radiopharmaceuticals (22)
Rare diseases (27)
Real estate (600)
Regulatory (2609)
Reports (6)
Research institute (92)
Schizophrenia (7)
Series A (17)
Series B (7)
Service/supplier (1)
Sickle cell disease (1)
Southern California (162)
Spinal muscular atrophy (4)
Startups (423)
Stomach cancer (2)
Supply chain (8)
United States (1326)
Vaccines (24)
Venture capitalists (2)
Weight loss (2)
Women's health (1)
Date
Today (13)
Last 7 days (70)
Last 30 days (222)
Last 365 days (2937)
2025 (898)
2024 (3260)
2023 (3821)
2022 (7023)
2021 (6374)
2020 (5872)
2019 (3863)
2018 (3010)
2017 (3560)
2016 (3171)
2015 (4031)
2014 (3022)
2013 (2600)
2012 (2775)
2011 (2902)
2010 (2663)
Location
Africa (79)
Alabama (1)
Arizona (8)
Asia (21425)
Australia (2433)
California (352)
Canada (225)
China (172)
Colorado (4)
Connecticut (14)
Delaware (4)
Europe (12462)
Florida (22)
Georgia (7)
Illinois (16)
India (11)
Indiana (4)
Japan (82)
Kansas (5)
Louisiana (1)
Maine (4)
Maryland (75)
Massachusetts (243)
Michigan (2)
Minnesota (27)
Missouri (3)
Nebraska (1)
Nevada (1)
New Jersey (201)
New York (148)
North Carolina (61)
Northern California (138)
Ohio (2)
Oregon (1)
Pennsylvania (54)
South America (106)
Southern California (162)
Tennessee (1)
Texas (28)
Utah (13)
Virginia (25)
Washington D.C. (2)
Washington State (17)
Wisconsin (6)
70,011 Results for "keymed ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Keymed Biosciences Announces Annual Results of 2024
March 27, 2025
·
12 min read
Press Releases
Keymed Biosciences Announces Approval of IND for CM518D1 by the National Medical Products Administration of China for the Treatment of Solid Tumors
April 25, 2025
·
2 min read
Press Releases
Keymed Biosciences Announces Approval of IND for CM518D1 by the National Medical Products Administration of China for the Treatment of Gastrointestinal Cancers
April 25, 2025
·
2 min read
Press Releases
Keymed Biosciences Announces Approval of Stapokibart For the Treatment of Seasonal Allergic Rhinitis
February 9, 2025
·
2 min read
Press Releases
Keymed Biosciences Announces Approval Of Stapokibart For The Treatment Of Chronic Rhinosinusitis With Nasal Polyposis
December 23, 2024
·
2 min read
Press Releases
InnoCare and KeyMed Jointly Announce the License Agreement with Prolium for CD20xCD3 Bispecific Antibody ICP-B02
January 20, 2025
·
3 min read
Business
Keymed Biosciences Announces 2023 Annual Results and Business Updates
Keymed Biosciences Inc. (HKEX: 02162) today announced its 2023 annual results, along with recent pipeline highlights and corporate updates.
March 26, 2024
·
9 min read
Keymed Biosciences Announces Safety and Efficacy Results of CM313 for Primary Immune Thrombocytopenia Published in NEJM
Keymed Biosciences Inc. announced that Lei Zhang/Renchi Yang’s team from the Institute of Hematology, Chinese Academy of Medical Sciences has recently published a research paper entitled “A Novel Anti-CD38 Monoclonal Antibody for Treating Immune Thrombocytopenia” in the New England Journal of Medicine.
June 20, 2024
·
2 min read
Business
Keymed Biosciences Announces Interim Results for First Half of 2024
August 27, 2024
·
8 min read
Press Releases
Medicus Pharma Ltd. Announces a Binding Letter of Intent to Acquire Antev Ltd. for ~US$75 Million in a Share Exchange Transaction
Antev Shareholders to Receive Aggregate ~19% Equity Stake in Medicus, Plus US$65 Million in Contingent Payments
April 28, 2025
·
10 min read
1 of 7,002
Next
